Good post & I agree. It is always case by case basis & a multitude of valuation metrics to be used. I haven’t studied enough of this business to comment more but mine is a guiding statement that comparing P/S of Syngene & saying PP is undervalued is not right.
I have also seen posts on social media by experts who too are valuing P/S way & could probably be misguiding new investors.
The caution I want to give is – the experts may have very diversified & large portfolios but the new retail investors put entire money on 1 stock expecting it to double basis the aforementioned analysis.
| Subscribe To Our Free Newsletter |
